Investors

Vysens B.V. is a Dutch Start-up company in the field of biomolecular interaction analysis (BIA). 

When looking into biotechnological laboratory markets, we were triggered by some issues:

• ELISA is more than 50 Years in use, although it is time-consuming and is costing expensive materials.
• SPR-systems can only be used by 'SPR-experts' which limits the application.
• When doing research on SARS-CoV-2, we discovered that not just the amount of antibodies in patient serum was important for the severity of the disease but also the avidity of the antibodies versus the virus.
• More and more emphasis is being laid on the relationship between antibodies and cells, yet, the avidity of cells cannot be measured.
• In case of Point-of-Care testing, the avidity of the anitbodies versus pathogens can be of importance as demonstrated in our SARS-CoV-2 research.

We have invented solutions for all of the above issues by generating one simple and solid backbone (5 patents, ongoing). Our system is functioning in instruments that are solving the issues stated above.

We are bringing two instruments to the market, the AutoVysion which can be distributed by internet and distributors and the CellVysion that will be distributed by more knowledge-intensive channels. The hardware of these instruments is based on the same principles.

While medicine has centred on standardized procedures, the technological progress makes it possible to make treatments tailor-made. A corner stone for tailor made treatments is tailor made testing. 

The AutoVysion: bringing photonics in biotech laboratories

Our AutoVysion is easy to use and focuses on biotech/biochem laboratories. The AutoVysion makes life easier for the researcher. In 30 minutes, antibodies (including patient serum) can be tested, coupling methos can be tested and incoming/outgoing antibodies can be characterized. This instrument doesn't need any training and functions fully automatically.

Revolutionizing Diagnostics with Advanced SPR Technology

Our pioneering product, the CellVysion SPR imager, is redefining the possibilities within diagnostics by offering precise, real-time insights into biomolecular interactions. This unparalleled accuracy in characterizing antibodies and cellular interactions is not just enhancing research capabilities but is also setting new standards in diagnostic methodologies.

Enhancing Diagnostic Precision

The core of modern diagnostics lies in the ability to detect and quantify biomarkers accurately and efficiently. CellVysion leverages SPR technology to provide this with unmatched precision, facilitating early detection, accurate disease characterization, and monitoring of treatment responses. This label-free and real-time detection capability is crucial for developing diagnostic assays that are not only sensitive but also specific to the biomarkers of interest, thus ensuring reliable results that healthcare professionals can trust.

Bridging Research and Clinical Practice

CellVysion serves as a vital bridge between the research laboratory and the clinical setting. By offering a detailed understanding of disease mechanisms at the molecular level, it enables the translation of research findings into practical diagnostic tools. This seamless transition from bench to bedside accelerates the development of novel diagnostics, helping to identify disease states and predispositions more effectively. As a result, clinicians can make more informed decisions, tailor treatments to individual patients, and improve overall healthcare outcomes.

Driving Innovations in Personalized Medicine

The future of medicine lies in personalization, where treatments and diagnostics are tailored to the unique genetic makeup of each individual. Vysens' SPR technology is instrumental in realizing this vision by enabling the detailed analysis of patient-specific biomolecular interactions. This capability is vital for identifying unique biomarkers, understanding individual disease profiles, and developing personalized diagnostic assays. Consequently, CellVysion is not just a tool for research but a cornerstone of personalized medicine, facilitating targeted therapies and customized care plans that significantly improve patient outcomes.

Collaborative Efforts for Diagnostic Advancements

Vysens is committed to advancing diagnostic technologies through collaborative efforts with researchers, clinicians, and industry partners. By sharing knowledge, resources, and expertise, we aim to unlock new diagnostic potentials and address the pressing challenges in healthcare. Our technology is designed to adapt to the evolving needs of the diagnostic community, ensuring that we remain at the forefront of scientific innovation and clinical application.

Empowering Diagnostics for a Healthier Tomorrow

Our mission goes beyond developing technology; it's about empowering diagnostics to create a healthier tomorrow. We invite the scientific and medical communities to join us in leveraging the CellVysion SPR imager's capabilities to push the boundaries of what's possible in diagnostics. Together, we can transform the landscape of healthcare, making disease detection more accurate, treatment more effective, and patient care more personalized.